The global scramble for Keytruda has exposed a quiet crisis in modern medicine: when a life-saving drug becomes a financial instrument, patients pay the price in more ways than one. From Vienna to Vitória, from courtroom battles to clandestine online markets, the story of pembrolizumab is no longer just about oncology—it’s about power, patent law, and the erosion of trust in a healthcare system increasingly beholden to corporate logic.
This isn’t merely a tale of soaring drug prices. It’s a case study in how pharmaceutical innovation, once hailed as a triumph of science, can morph into a mechanism of exclusion when untethered from equitable access. The International Consortium of Investigative Journalists’ Cancer Calculus investigation revealed that Merck’s Keytruda, even as clinically transformative, has grow a linchpin in a global disparity where wealth dictates survival. But beneath the headlines of $200,000 annual treatment costs lies a deeper, less visible economy: a burgeoning black market for diverted doses, inflated prescribing practices straining public systems, and a judicialization of healthcare that turns patients into litigants fighting for their lives.
The roots of this crisis trace back to Keytruda’s mechanism of action. As a PD-1 inhibitor, pembrolizumab unleashes the immune system to recognize and destroy cancer cells—a breakthrough that earned it FDA approval in 2014 for metastatic melanoma. Since then, its indications have expanded to over 30 cancer types, including lung, bladder, and hepatocellular carcinoma. This expansion, while medically justified in many cases, has been aggressively pursued by Merck through a strategy known as “evergreening”: securing secondary patents on formulations, dosing regimens, and diagnostic companion tests to delay generic competition. According to a 2023 analysis by the Initiative for Medicines, Access & Knowledge (I-MAK), Merck filed over 70 patent applications related to Keytruda between 2015 and 2022, potentially extending its market exclusivity well beyond 2030.
This patent thicket has direct consequences. In lower-income countries, where health budgets are already stretched thin, the cost of Keytruda often exceeds annual per capita GDP. In India, for example, a single dose can cost more than the average worker earns in three months. Yet, despite voluntary licensing agreements offered by Merck through the Medicines Patent Pool, uptake has been minimal—partly due to restrictive terms that limit production to a handful of manufacturers and exclude middle-income nations like Brazil and South Africa, where need is greatest.
The result? A shadow economy has emerged. In Eastern Europe and Southeast Asia, investigators have traced diverted Keytruda vials from hospital waste streams to online marketplaces where doses sell for 300–500% of their official price. In Romania, prosecutors uncovered a network in 2024 that siphoned unused drug from oncology wards and relabeled it for resale—a scheme enabled by weak tracking systems and fragmented oversight. “We’re seeing the same patterns as with opioids,” said Dr. Elena Vasilescu, a pharmaceutical crime specialist at Europol, in a recent interview. “Except here, the demand isn’t driven by addiction—it’s driven by desperation. People aren’t getting high; they’re trying to stay alive.”
Compounding the crisis is Merck’s shift to a fixed 200-milligram dose for all patients, regardless of weight or tumor type—a departure from the weight-based dosing used in early clinical trials. Oncologists like Dr. Daniel Goldstein of Tel Aviv’s Sheba Medical Center have long argued this change lacks pharmacological justification. “If a 50-kilogram patient and a 120-kilogram patient receive the same dose, we’re either overtreating the smaller person or undertreating the larger one,” Goldstein explained in a 2023 interview with Der Spiegel. His subsequent research, published in JAMA Oncology in early 2024, demonstrated that 25% lower doses achieved equivalent tumor shrinkage and survival rates in non-small cell lung cancer—suggesting billions could be saved globally without sacrificing efficacy.
Yet Merck has resisted revising its labeling. Internal documents obtained by ICIJ display the company evaluated dose-reducing strategies as early as 2019 but concluded that maintaining the 200mg standard “preserves revenue integrity” across diverse healthcare systems. The financial stakes are immense: Keytruda generated $25 billion in global sales in 2023 alone, accounting for nearly a third of Merck’s total pharmaceutical revenue. For context, that exceeds the annual healthcare budgets of countries like Portugal, Novel Zealand, and Uruguay combined.
The burden falls hardest on public insurers. In Austria, where hospital drugs face no price ceilings, Keytruda consumes over 12% of the national pharmaceutical budget despite representing less than 0.5% of prescriptions. Similar strains appear in Canada’s provincial drug plans and the UK’s NHS, where immunotherapy now drives more than 40% of cancer drug spending growth. Faced with unsustainable costs, some systems have begun imposing restrictive access criteria—requiring patients to fail cheaper therapies first or limiting treatment duration—prompting outrage from patient advocacy groups.
This has fueled the over-judicialization of care. In the United States, patients have filed over 1,200 lawsuits since 2020 alleging wrongful denial of Keytruda by insurers, according to a tracker by Georgetown University’s O’Neill Institute. In Brazil, public prosecutors have sued Merck twice in the past year for alleged abuse of economic power, citing its refusal to lower prices despite documented public health impact. One landmark case in São Paulo resulted in a court ordering the state to provide Keytruda to a metastatic melanoma patient after her health plan denied coverage—a ruling echoed in judgments from Mexico City to Manila.
“We’re witnessing the commodification of hope,” said Dr. Ananya Rai, a bioethicist at the University of Cape Town who studies global oncology access. “When a drug’s price is disconnected from its cost of production and tied instead to what the market can bear, we stop treating illness and start auctioning off time.”
The path forward requires more than moral appeals. Policy interventions like compulsory licensing—used effectively during the HIV/AIDS crisis—could be triggered for Keytruda in countries facing public health emergencies. Reference pricing models, where nations benchmark drug costs against those in similar economies, have shown promise in Europe. And transparency mandates, such as the U.S. Inflation Reduction Act’s requirement for Medicare to negotiate prices on select high-cost drugs, offer a template for broader reform.
But none of this will shift without pressure. Patients, clinicians, and journalists must continue to expose the disconnect between pharmaceutical profitability and human need. Because when a medicine meant to unleash the body’s defenses becomes a tool for extracting wealth from the vulnerable, the true malignancy isn’t in the tumor—it’s in the system that allows it to thrive.
What would it take for you to believe that lifesaving medicine should be a right, not a leveraged asset? Share your thoughts below—this conversation is just beginning.
